Site-directed gene mutation at mixed sequence targets by psoralen-conjugated pseudo-complementary peptide nucleic acids by Kim, Ki-Hyun et al.
7604–7613 Nucleic Acids Research, 2007, Vol. 35, No. 22 Published online 30 October 2007
doi:10.1093/nar/gkm666
Site-directed gene mutation at mixed
sequence targets by psoralen-conjugated
pseudo-complementary peptide nucleic acids
Ki-Hyun Kim
1, Peter E. Nielsen
2 and Peter M. Glazer
1,*
1Departments of Therapeutic Radiology and Genetics, Yale University School of Medicine, P.O. Box 208040,
New Haven, CT 06520-8040, USA and
2Department of Cellular and Molecular Medicine, University of
Copenhagen, The Panum Institute, Blegdamsvej 3, Copenhagen, DK-2200, Denmark
Received April 11, 2007; Revised August 10, 2007; Accepted August 13, 2007
ABSTRACT
Sequence-specific DNA-binding molecules such as
triple helix-forming oligonucleotides (TFOs) provide
a means for inducing site-specific mutagenesis and
recombination at chromosomal sites in mammalian
cells. However, the utility of TFOs is limited by the
requirement for homopurine stretches in the target
duplex DNA. Here, we report the use of pseudo-
complementary peptide nucleic acids (pcPNAs) for
intracellular gene targeting at mixed sequence sites.
Due to steric hindrance, pcPNAs are unable to form
pcPNA–pcPNA duplexes but can bind to comple-
mentary DNA sequences by Watson–Crick pairing
via double duplex-invasion complex formation. We
show that psoralen-conjugated pcPNAs can deliver
site-specific photoadducts and mediate targeted
gene modification within both episomal and chro-
mosomal DNA in mammalian cells without detect-
able off-target effects. Most of the induced
psoralen-pcPNA mutations were single-base sub-
stitutions and deletions at the predicted pcPNA-
binding sites. The pcPNA-directed mutagenesis was
found to be dependent on PNA concentration and
UVA dose and required matched pairs of pcPNAs.
Neither of the individual pcPNAs alone had any
effect nor did complementary PNA pairs of the same
sequence. These results identify pcPNAs as new
tools for site-specific gene modification in mamma-
lian cells without purine sequence restriction,
thereby providing a general strategy for designing
gene targeting molecules.
INTRODUCTION
Gene targeting technology using site-speciﬁc DNA-
binding molecules is a promising tool for molecular
biology and possibly in vivo therapy. By binding to
DNA, such ligands can modulate basic gene functions,
such as transcription, repair, recombination and replica-
tion. In certain cases, these ligands can also be used to
modify speciﬁc genes at the sequence level via the
induction of mutagenesis and recombination. A number
of DNA-binding ligands have been developed for site-
speciﬁc gene control, including polyamides that bind in
the DNA minor groove (1,2); engineered zinc-ﬁnger
peptides formed by modular combinations of predeﬁned
zinc ﬁngers that recognize speciﬁc DNA sequences
(3,4); and triple helix-forming oligonucleotides (TFOs)
that can bind in the major groove of duplex DNA at
polypurine/polypyrimidine stretches via Hoogsteen or
reverse Hoogsteen base pairing in a sequence-speciﬁc
manner (5,6).
Peptide nucleic acids (PNAs) are synthetic DNA mimics
which contain 2-aminoethyl glycine linkages instead of
the phosphodiester backbone of oligonucleotides (7,8).
However, PNAs still have nucleobases connected via
methylene carbonyl linkers, allowing them to form PNA–
DNA or PNA–RNA duplexes via Watson–Crick base
pairing with high aﬃnity and sequence-speciﬁcity (9,10).
Triplex formation by homopyrimidine PNAs on double-
stranded DNA containing a homopurine sequence results
in the formation of very stable PNA/DNA/PNA triplex
invasion complexes, sometimes referred to as PNA clamps
(11,12). Studies have shown that triplex invasion com-
plexes formed by PNAs can modulate gene expression in
cells via transcription regulation (13–17), replication
inhibition (18), and site-speciﬁc induction of mutagenesis
(19,20) or recombination via stimulation of DNA repair
pathways (21).
However, the current application of TFOs or PNAs
for gene targeting is limited by the homopurine/homo-
pyrimidine target sequence requirement for triple helix
formation. To overcome this sequence restriction, the use
of pseudo-complementary PNAs (pcPNAs) has been
proposed (15). Based on the ﬁnding that PNAs can form
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Watson–Crick base recognition, it was proposed to use
two PNA strands to create a stable double-duplex
invasion complex. However, this was shown to require
that the two PNA strands be pseudo-complementary to
each other, in order to prevent the otherwise favored
formation of PNA–PNA duplexes. Such pcPNAs
are therefore synthesized to contain 2,6-diaminopurine
and 6-thiouracil instead of adenine and thymine, respec-
tively. Due to steric hindrance between these substituted
nucleobase pairs, pcPNAs containing at least 40% A and
T are unable to bind eﬃciently to each other, yet are still
capable of binding to complementary DNA molecules.
Because pcPNAs can form double-duplex invasion com-
plexes at mixed sequences, they oﬀer the ability to
overcome the sequence limitation of triplex-mediated
gene targeting and can do so via straightforward
Watson–Crick base pairing rules (22,23). Key initial
studies, performed in vitro, have demonstrated that
pcPNAs can be used to inhibit transcription initiation
by T7 RNA polymerase (15); to block the access of
methylation/restriction enzymes to duplex DNA (24,25);
and to modify double-stranded DNA using a DNA-
modifying agent (26). However, while these prior in vitro
studies were extensive, the ability of these molecules to
target chromosomal DNA inside living cells was not tested
and remained unknown.
In the work reported here, we have evaluated the
feasibility of using pcPNAs to introduce site-speciﬁc
psoralen photoadducts in chromosomal DNA in living
cells as a tool for gene modiﬁcation. Psoralen is a tricyclic
planar DNA-intercalating compound, which reacts cova-
lently to double-stranded DNA upon irradiation with long
wavelength UV light (320–400nm) (27), and we have
recently shown that speciﬁc sequence targeting of the
psoralenphotoreactioncanbeaccomplishedusingapairof
pcPNAs of which one is conjugated to 8-alkoxypsoralen
(28). We designed a similar pair of pcPNAs, one of
which was conjugated with psoralen, to recognize a
target site within the supF reporter gene by double-
duplex strand invasion. We show that this pair of
pcPNAs can mediate site-directed photoadduct forma-
tion in vitro and can induce mutagenesis in the supF
target gene both in an episomal shuttle vector and at a
chromosomal site in mouse cells. The induced photo-
adducts were found to occur at the predicted A:T base
pairs adjacent to the pcPNA-binding site, and the
pcPNA-induced mutations were detected at the target
site at frequencies of 1.15% in the episome and 0.04% in
the chromosome. The pcPNA-mediated gene targeting
showed a dependence on PNA concentration and UVA
dose and required matched pairs of pcPNAs. Overall,
this work provides the basis for a gene targeting strategy
in mammalian cells with minimal sequence restriction.
MATERIALS AND METHODS
PNA molecules
The PNA molecules used in this study are listed in Table 1.
‘D’ and ‘SU’ indicate 2,6 diaminopurine and 6-thiouracil,
respectively. The pcPNA pair, PNA 2640 and PNA 2641,
were synthesized and puriﬁed as described previously
(20,28). They were determined to be homogeneous based
on HPLC and exhibited one major peak at the expected
mass as analyzed by MALDI-TOF mass spectroscopy.
8-Methoxycarbonylpsoralen (denoted as Pso) was con-
jugated to the N-terminus of the pcPNA while on the solid
support via two eg1 ﬂexible linker units (eg1: 8-amino-2,
6-dioxaoctaninic acid). Two lysine amino acids were
attached to increase solubility and binding aﬃnity to
DNA. CTR-ssPNA and Pso-ssPNA were synthesized by
BioSynthesis, Inc. (Lewisville, TX, USA), puriﬁed by
HPLC and analyzed by mass spectrometry.
Plasmid construction
The SV40 shuttle vector pPCMU was derived from
pLSG3T7 (20). It contains a 10-bp target site with 40%
A:T content within the coding region of the supF gene
(bp 139-148) that was chosen for pcPNA binding. Next to
the pcPNA-binding site, there are 50-TpA and 50-ApT base
steps (bp 134–135 and bp 137–138, respectively), which are
preferential intercalation sites for psoralen. The pcPNAs
conjugated with psoralen were designed to introduce
site-speciﬁc photoadduct at these sites. In addition, the
plasmid pPCMU contains a T7 promoter further down-
stream of the coding region, which was used for an in vitro
transcription elongation arrest assay utilizing T7 RNA
polymerase.
Invitro binding and photoadduct formation
To form double-duplex invasion complexes, various
concentrations of pcPNA pairs (PNA2640/2641), as
indicated, were incubated with a desired amount (0.5mg)
of pPCMU in TE buﬀer with 10mM KCl for 16h at 378C
(In prior studies, we have found that pcPNA binding to a
plasmid substrate is near maximal within 4h of incubation
under these conditions and essentially at maximum at
16h). For photoadduct formation, UVA irradiation
(365nm) was administered to the pcPNAs (PNA 2640/
2641) and plasmid mixtures at a dose of 1.8J/cm
2 on ice.
The pcPNA–plasmid mixtures were then digested with
BspEI. After puriﬁcation of the linearized template, a
transcription elongation arrest assay was performed in
30ml of transcription reaction mixture [1mM NTP (except
UTP), 0.2mM UTP 2mCi (a-P
32)UTP, 5mM DTT, and
10 units of T7 RNA polymerase] at 378C for 10min. The
reaction was terminated through the addition of a stop
buﬀer, and the transcription mixture was analyzed on a
Table 1. PNA sequences
PNA PNA sequence (N0 to C0)
PNA 2640 Pso-(eg1)2-(Lys)2-CSUG CCG SUCD SU-Lys-NH2
PNA 2641 H-Lys-Lys-DSUG DCG GCD G-Lys-NH2
CTR-ssPNA H-Lys-Lys-Lys-ATG ACG GCA G-Lys
Pso-ssPNA Pso-(eg1)2-(Lys)3-CTG CCG TCA TCG ACT-Lys-NH2
PNAs are listed from N to C terminus.
D, 2,6-diaminopurine; SU, 6-thiouracil; Pso, psoralen; eg1, 8-amino-2,
6-dioxaoctaninic acid.
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lamide) gel containing 7M urea in TBE buﬀer (90mM
Tris at pH 8.0, 90mM boric acid and 2mM EDTA). As a
size marker, an RNA-sequencing ladder was used.
In parallel, transcription products with non-irradiated
pcPNA–plasmid mixtures were included as a control.
Radioactive bands were visualized by autoradiography
using amplifying screens and Kodak BioMax MR ﬁlm
exposed at  708C for 16h. For the analysis of photo-
adduct formation eﬃciency, the amount of transcription
product was measured by densitometric scanning of the
autoradiogram using ImageQuant software. Photoadduct
formation eﬃciency was derived from the ratio of the
run-oﬀ product and the truncated elongation bands. The
photoadduct formation eﬃciencies were analyzed by
Prism (GraphPad Software, Inc.) and presented as a
function of PNA concentration.
To assay for the dependence on pcPNAs for targeting,
PNAs were incubated alone or in combination and at
various concentrations (as indicated) with pPCMU
(0.5mg) in TE (pH. 7.4) at 378C for 16h to allow
formation of strand invasion complexes. UVA irradiation
was administered at a dose of 1.8J/cm
2, and the irradiated
PNA–plasmid mixtures were digested with BspEI restric-
tion enzyme. The transcription elongation arrest assay was
performed and analyzed as described above.
Mutagenesis assayinan episomal shuttle vector
Monkey COS-7 cells were obtained from ATCC
(1651-CRL) and maintained in DMEM supplemented
with 10% fetal bovine serum (Gibco BRL, division of
Invitrogen). Various concentrations of pcPNAs (as
indicated) were incubated at 378C for 16h with a ﬁxed
amount of pPCMU (5mg) to form double-duplex invasion
complexes. After UVA irradiation (1.8J/cm
2) on ice, the
UVA-irradiated pcPNA–pPCMU mixtures (4mg) were
transfected into COS cells (10
6) using cationic lipid
transfection reagent, Geneporter2 (Gene Therapy
Systems, Inc.). Cationic lipids were used in this case
because the negatively charged plasmid DNA within the
PNA/plasmid complex allows for the use of this transfec-
tion method. In the case of transfection of PNAs alone,
electroporation must be used because the PNAs them-
selves do not have a negative charge (see subsequently).
Plasmid DNA was isolated for analysis 48–72h post-
transfection using a modiﬁed alkaline lysis procedure, as
described previously (20,29). The isolated DNA was
digested with DpnI and RNase A at 378C for 1h, puriﬁed
using phenol/chloroform/isoamyl alcohol (25:24:1) extrac-
tion, and precipitated with ethanol. The DpnI digestion
eliminates unreplicated plasmid DNAs that have not
acquired the mammalian methylation pattern. The puri-
ﬁed DNA was transformed into indicator bacteria,
Escherichia coli MBM7070, by electroporation (Bio-Rad,
setting 25mF/250W/1800V, using 0.1-cm cuvette), and
mutant colonies containing inactivated supF genes,
unable to suppress the amber mutation in the host cell
b-galactosidase gene, were detected by visual inspection as
white colonies among the blue wild-type. The mutation
frequency was determined as the ratio of white (mutant)
colonies to total colonies. This frequency was presented
with the photoadduct formation eﬃciencies as a function
of the PNA concentration. The mutant plasmids were then
extracted and puriﬁed for further analysis of mutation
pattern by DNA sequencing. A parallel experiment
was performed with non-irradiated pcPNAs–pPCMU.
The results obtained were compared with those from the
irradiated pcPNA–pPCMU mixtures.
Chromosomal gene targeting assay
Mouse ﬁbroblasts (LN12 cells) with multiple chromoso-
mally integrated copies of  vector DNA containing the
supF (target) and cII (non-targeted) mutation reporter
genes were maintained in DMEM (supplemented with
10% fetal bovine serum) containing G418at 0.4mg/ml
(Gibco BRL, division of Invitrogen) (30,31). Selected
PNAs alone or in combination (as indicated)
were transfected at a 5mM concentration into cells
(10
6 cells/100ml) via electroporation (Bio-Rad, setting
500mF/1 /320V, using a 0.4cm cuvette). Cells were
incubated at 378C and UVA irradiated 6h later (or not) at
a dose of 1.8J/cm
2. Cells were collected for preparation of
genomic DNA fours days following treatment, and
lambda vector rescue and analysis of mutagenesis in the
supF and cII genes were performed as described previously
(30,31). The assay for supF mutagenesis is based on
suppression of an amber stop codon in lacZ (amber)
indicator bacteria, visualized as blue (wild-type) or color-
less (mutant) plaques (29). The assay for cII gene
mutagenesis is based on plaque formation at 308Co na n
hﬂ host. Only phage with cII mutations form plaques
under such conditions (32).
RESULTS
Design ofpcPNA molecules
To test the gene targeting ability of pcPNAs, we designed
a pair of pcPNAs (PNA2640 and PNA 2641) capable of
forming a double-duplex invasion complex at a selected
site within the supF reporter gene (Figure 1A). This site
consists of a 10 base pair mixed purine–pyrimidine
sequence from position 139 to 148, which was chosen as
an example of a site at which triple helix formation would
not be possible. In addition, one of the pcPNAs
(PNA2640) was conjugated with a psoralen derivative
(8-methoxypsoralen) via two ﬂexible linker units (eg1:
8-amino-2, 6-dioxaotanonic acid) so that pcPNA binding
could be used to direct psoralen photoadduct formation at
the 50-TpA or the 50-ApT sites that are 1 and 4bp away
from the end of the PNA-binding site, respectively. Two
lysines were also attached to the N terminus of each of the
pcPNAs to provide increased aqueous solubility and to
enhance the binding aﬃnity to DNA.
Site-specific photoadduct formation by pcPNAs conjugated
with psoralen
To evaluate the ability of the pcPNA pair (2640 and 2641)
to direct site-speciﬁc photoadduct formation in the target
duplex, we used an assay to detect psoralen crosslinks
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elongation by T7 phage RNA polymerase in vitro. Plasmid
pPCMU contains the supF reporter gene adjacent to a T7
promoter, which is situated at the 30 end of the supF
coding region, such that in vitro transcription using T7
RNA polymerase will use the top strand of the plasmid as
a template (Figure 1A). PNA2640/2641 and pPCMU
DNA mixtures (at increasing PNA concentrations, as
indicated) were treated or not with UVA irradiation and
used as a substrate in the transcription elongation arrest
assay (Figure 1B). Bands indicating truncation products
were present only in the samples containing UVA-
irradiated mixtures, indicating a requirement for photo-
adduct formation. In addition, the intensity of the
truncated band increases with increasing PNA concentra-
tion, demonstrating PNA concentration dependence.
In comparison to the sequence ladder, the position of
the truncated bands corresponds to the size expected
based on psoralen adduct formation at the 50-TpA and/or
50-ApT sites adjacent to PNA target site. These results
Figure 1. Analysis of photoadducts formed by pcPNAs conjugated with psoralen. (A) PNA binding and double-duplex strand invasion complex
formation in the supF gene from position 139 to 148. The pcPNAs, in which all adenines and thymines are substituted by 2,6-diaminopurine (D) and
6-thiouracil (sU), bind to a target site with a mixed purine–pyrimidine sequence via double-duplex invasion. One of the pcPNAs (PNA2640) was
conjugated with a psoralen derivative (8-methoxypsoralen) via ﬂexible linkers (as described in Table 1). The target site is composed of two domains: a
mixed purine–pyrimidine sequence 10bp in length containing 40% A:T content for pcPNA binding and nearby 50-TpA and 50-ApT sites for
photoadduct formation by psoralen, 1 and 4bp away from the end of the pcPNA-binding site, respectively. (B) Determination of pcPNA-mediated
photoadduct formation by transcription elongation arrest assay using T7 RNA polymerase. The transcription elongation arrest assay was performed
with BspEI-linearized, irradiated or non-irradiated pcPNA–pPCMU mixtures and analyzed. The site of polymerase arrest was determined by
comparison with an RNA-sequencing ladder. (C) Requirement for a matched pair of pcPNAs for eﬃcient targeting at mixed purine–pyrimidine
sequence in a plasmid substrate in vitro. The matched pair of pcPNAs (2640 and 2641) or pcPNAs individually (as indicated), were incubated with a
ﬁxed amount of pPCMU, as described above, to test the ability to direct psoralen adduct formation on the target sequence in the plasmid in vitro.
After UVA-irradiation, the transcription elongation arrest assay was performed with BspEI-linearized, irradiated PNA–pPCMU mixtures, and
transcription products were analyzed as above. As an additional control, PNA2640 was mixed with CTR-ssPNA (Table 1) which has the same
sequence as PNA2641 but lacks the pseudocomplementary bases and contains only natural A and T nucleobases.
Nucleic Acids Research, 2007, Vol. 35, No. 22 7607show that a pair of pcPNAs, with one conjugated to
psoralen, can direct a site-speciﬁc photoadduct to duplex
DNA. Note that in the absence of psoralen photoadduct
formation, elongation by T7 RNA polymerase is not
inhibited by the pcPNA binding alone, a result consistent
with previous reports (15,28).
Requirement foramatched pair ofpcPNAs
Using the T7 polymerase arrest assay, we asked whether
the combination of the two pcPNAs, as opposed to either
pcPNA alone, is required for the generation of the site-
directed psoralen adduct. Following incubation of the
plasmid pPCMU with individual or paired pcPNAs (or a
single-stranded PNA control), the samples were irradiated
and the transcription elongation arrest assay was per-
formed as above. Bands corresponding to elongation
arrest were detected only in the samples containing both
pcPNAs (PNA2640/2641) (Figure 1C). This result demon-
strates that individual, single-stranded PNAs do not
mediate suﬃcient strand invasion and binding to promote
detectable psoralen delivery and adduct formation. This is
consistent with the model that a pair of pcPNAs is
necessary to aﬀord suﬃcient free energy for double-duplex
invasion complex formation by binding the two target
DNA strands simultaneously (15,28). As another control,
we tested the combination of PNA2640 (the pcPNA that is
linked to psoralen; Table 1) and the regular (i.e. non-
pseudocomplementary) PNA designated CTR-ssPNA
(Table 1), which is complementary to PNA2640 by
sequence. Because only one (2640) and not the other
(CTR-ssPNA) contains pseudocomplementary bases,
there is no steric hindrance to binding, and so there are
quenching eﬀects between these two molecules due to the
formation of very stable pcPNA/PNA duplexes.
Accordingly, there is no detectable photoadduct forma-
tion produced by this pair of molecules (Figure 1C).
Hence only pairs of PNA in which both molecules
contain pseudocomplementary bases are eﬀective in
this assay.
Site-directed mutagenesis targeted by pcPNAs to an
episomal shuttle vector invitro
To examine the ability of pcPNAs conjugated with
psoralen to induce site-speciﬁc gene modiﬁcation in
DNA, an episomal shuttle vector assay was used (20).
In this assay, the plasmid pPCMU, described above and
which contains the supF mutation-reporter gene, was used
as a shuttle vector since it carries both bacterial plasmid
and SV40 replication origins. Increasing concentrations
of pcPNAs were incubated with a ﬁxed amount of
pPCMU DNA in vitro, followed (or not, as indicated)
by UVA irradiation to induce photoadduct formation,
which was measured using the RNA polymerase arrest
assay (Figure 2A). The pcPNAs–pPCMU mixtures (with
or without UVA irradiation) were transfected into COS
cells, and the episomal pPCMU DNA was isolated 48h
later for genetic analysis of the supF gene via transfection
into indicator bacteria. The mutation frequency is
presented as a function of the PNA concentration
(Figure 2B). In the irradiated pcPNAs–pPCMU mixtures,
the mutation frequency was dependent on pcPNA
concentration and correlated with the degree of photo-
adduct formation. At a concentration of 0.8mM pcPNAs,
the photoadduct formation eﬃciency was 24%,
yielding an induced mutation frequency of 1.15%, which
was 19-fold higher than background. No mutagenesis
above background was observed in the non-irradiated
samples.
Mutation pattern induced by psoralen-conjugated pcPNAs
The mutation pattern induced by psoralen-conjugated
pcPNAs was determined by sequence analysis of supF
genes from 28 independent mutant colonies (Figure 2C).
The majority of mutations were point mutations contain-
ing base-substitutions at or around the targeted site for
psoralen photoadduct formation. In addition, several
deletion mutations near to or including the pcPNAs and
psoralen target site were found, consistent with the known
mutagenic eﬀect of psoralen crosslinks. These results
demonstrate that pcPNAs conjugated with psoralen can
introduce site-speciﬁc damage in a plasmid DNA in vitro
and that this site-directed damage, in the context of the
pcPNA strand invasion complex, is processed into
targeted mutations in mammalian cells.
Chromosomal gene targeting inmouse cells by pcPNAs
To determine the ability of pcPNAs to mediate chromo-
somal gene targeting in living cells, we used the mouse
LN12 cell as a model system. This cell line carries multiple
chromosomally integrated copies of the supF shuttle
vector that contains both the supF and the cII mutation
reporter genes. Phage vector rescue from mouse cell
genomic DNA using lambda in vitro packaging extracts
allows for reporter gene analysis by phage growth in
indicator bacteria (31). LN12 cells were transfected with
the matched pair of pcPNAs (2640/2641) via electropora-
tion, and 6h later the cells were irradiated or not with
UVA irradiation at a dose of 1.8J/cm
2 for psoralen
photoactivation. After 72h, cells were harvested for
genomic DNA preparation and vector rescue and analysis
(Figure 3A). Only the sample from cells transfected with
pcPNAs 2640/2641 and UVA-irradiated showed induced
mutagenesis above background (at a frequency of
0.036%). Samples without UVA-irradiation or without
the pair of pcPNAs did not show any mutagenesis above
background. As a measure of speciﬁcity, we analyzed
the mutation frequency in the non-targeted cII gene within
the same samples. The cII gene serves as a speciﬁcity
control because it does not contain the 10-bp binding site
for pcPNAs 2640/2641 (the closest sequence contains
four mismatches out of 10). There was no detectable
induction of mutations above background in the cII gene
by the pcPNAs.
Requirement for pairedpcPNAs forchromosomal
gene targeting
To test whether both pcPNAs are needed to mediate
the above gene targeting, we transfected LN12 cells with
either the pair of pcPNAs (2640 and 2641), 2640 alone
(which has the psoralen conjugate), 2641 alone, or another
7608 Nucleic Acids Research, 2007, Vol. 35, No. 22psoralen-conjugated PNA (Pso-ssPNA) with a similar
sequence to 2640 but without the modiﬁed pseudo-
complementary bases. The cells were subsequently UVA
irradiated as above, and chromosomal DNA was isolated
72h later for analysis of mutagenesis in the supF gene.
Only cells transfected with the pair of pcPNAs
(2640/2641) showed induced mutagenesis. In this set of
experiments, the combination of the pcPNAs, 2640 and
2641, induced mutations in the supF reporter gene at
a frequency of 0.030%, compared with frequencies of
0.004–0.008% for the individual single-stranded PNAs
(Figure 3B). Hence, in this assay, the pseudo-
complementary pcPNA pair is required for detectable
mutagenesis. Interestingly, it has been reported
that single-stranded PNAs can inhibit transcription in
a sequence-speciﬁc way when targeted to bind near
transcription start sites (33), suggesting that regions with
open conformations may be amenable to targeting by
individual PNA strands. However, our results suggest
that the enhanced strand invasion properties of matched
Figure 2. Targeted mutagenesis by pcPNAs conjugated with psoralen on an episomal vector transfected into mammalian cells. (A) Photoadduct
formation eﬃciency. After in vitro incubation of the pcPNAs (at the indicated concentrations) with the plasmid substrate to allow double-duplex
invasion complex formation, UVA irradiation was given and the photoadduct formation eﬃciency by pcPNAs2640/2641 was determined. This
eﬃciency was ﬁtted and presented as a function of PNA concentration. Error bars indicate standard error (SEM). (B) Mutation frequency induced
by pcPNAs conjugated to psoralen. The mutation frequencies of UVA-irradiated or non-irradiated psoralen-pcPNAs/vector complexes transfected
into COS cells were derived from the ratio of white colonies (representing mutants) to the total number of colonies (white plus blue) and presented as
a function of the PNA concentration. Experiments were performed four times, and error bars indicate standard error (SEM). (C) Pattern of mutation
induced in the episomal supF gene by pcPNAs2640/2641 plus UVA irradiation. The PNA-binding site is indicated by the underlining below the gene
sequence, and the start region of supF gene is indicated in bold. The single-base substitutions are listed above corresponding supF gene sequences.
Deletions are indicated by ‘-’ below the mutation site, and each line indicates the extent of an individual deletion mutant.
Nucleic Acids Research, 2007, Vol. 35, No. 22 7609pairs of pcPNAs may be required for eﬀective targeting
at other sites. As a further control, we transfected cells
with a combination of 2640 and CTR-ssPNA, a PNA
that is complementary rather than pseudo-complementary
to pcPNA2640, to test for a quenching eﬀect that
would be expected from PNA/pcPNA duplex formation.
This PNA/pcPNA pair was ineﬀective, demonstrating
that both PNAs must contain pseudo-complementary
bases.
Mutation patterns induced bypsoralen-conjugated pcPNAs
The pattern of induced mutations was determined by
DNA sequence analysis of supF genes in 39 independent
Figure 3. Targeted mutagenesis in the chromosomal supF gene using pcPNAs. (A) Speciﬁcity of pcPNA-directed mutagenesis in the chromosomally
integrated supF reporter gene in mouse cells. Selected PNAs, as indicated, were transfected into cells followed six hours later by UVA irradiation
(or not) at a dose of 1.8J/cm
2 for photoactivation of psoralen. Mutation frequencies in the supF gene (black bars) were determined following vector
rescue. For comparison, mutagenesis in the cII gene, which is also contained in the vector but does not contain the 10-bp target sequence for these
pcPNAs, was assayed as a speciﬁcity control (white bars). Experiments were performed four times, and error bars indicate standard error (SEM).
(B) Requirement for matched pairs of pcPNAs for chromosomal gene targeting. Selected individual or pairs of PNAs or pcPNAs (as indicated) were
transfected into LN12 cells and UVA irradiation was given as above. Mutation frequencies in the supF gene were determined as above. Experiments
were performed two times, and error bars indicate standard error (SEM). (C) Mutation pattern in the supF gene induced by pcPNAs conjugated to
psoralen. The PNA-binding site is indicated by the underlining below the gene sequence. The single-base substitutions are listed above corresponding
supF gene sequences. Deletions are indicated by ‘-’ below the mutation site, and each line indicates the extent of individual deletion mutants. The four
large deletion mutations all end at the same 30 position.
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mutations were T:A to G:C transversions at bp 138,
within the 50-ApT site (a preferred psoralen intercalation
site) and next to the pcPNA-binding site. Another
transversion, G:C to C:G was found at bp 141 within
the pcPNA binding site. In addition, deletion mutations
near to or encompassing the pcPNA-binding site were
seen, as with the episomal vector. Some scattered
mutations were also seen, consistent with an expected
20% contribution of background mutations to the
spectrum. The spectra of mutations induced in the
chromosomal target (Figure 3) is not identical to
that produced in the episomal target (Figure 2). This is
not surprising, because prior studies involving psoralen-
linked TFOs have shown clear diﬀerences in spectra
between episomal and chromosomal targets (31).
Nonetheless, the induced chromosomal mutations are
clearly targeted to the intended psoralen intercalation site
adjacent to the pcPNA binding site, and so the data shown
here demonstrates that pcPNAs conjugated with psoralen
can introduce site-speciﬁc photoadducts at chromosomal
sites in mammalian cells and can do so at non-polypurine,
mixed sequences.
DISCUSSION
In the work presented here, we have established the ability
of a matched pair of pcPNAs to direct site-speciﬁc DNA
modiﬁcation at non-polypurine, mixed sequence targets
within both episomal and chromosomal genes. With one
pcPNA in the pair linked to psoralen, the binding of the
pcPNAs to the target DNA was designed to deliver a
psoralen adduct to a speciﬁc site within the supF reporter
gene. In vitro, pcPNA binding was shown to mediate
formation of base-pair-speciﬁc psoralen adducts as
determined by inhibition of transcript elongation by T7
RNA polymerase in vitro. The formation of such adducts
was shown to be dependent on pcPNA concentration and
on UVA irradiation for psoralen photoactivation.
In contrast, a single-stranded psoralen-linked PNA
targeted to this site did not mediate detectable photo-
adduct formation.
We used pcPNAs to target psoralen adducts to the supF
gene in an SV40-based shuttle vector in vitro. Upon
transfection of the pcPNA/shuttle vector complexes into
COS cells and then rescue into indicator bacteria, base-
pair-speciﬁc mutations were detected in the supF gene at
frequencies in the range of 1%.
This work was extended to experiments to target the
supF reporter gene carried within a chromosomally
integrated lambda shuttle vector in mouse LN12 cells.
Transfection of the LN12 cells with the pcPNAs, followed
by UVA irradiation of the cells, yielded base-pair-speciﬁc
mutations in the supF gene, consistent with site-speciﬁc
binding by the pcPNAs at the targeted chromosomal site
within the mouse cells. Under conditions that produced
pso-pcPNA-targeted mutagenesis in the supF gene, there
was no detectable induced mutagenesis in the cII gene
following treatment with pso-pcPNAs (even with UVA
irradiation). These data demonstrate the sequence
speciﬁcity of pcPNAs for the complementary DNA
target sequence and suggest that there are no major oﬀ-
target eﬀects of pso-pcPNAs on DNA metabolism in
the absence of the cognate-binding site. However, the cII
results do not completely rule out the possibility of
low-level eﬀects elsewhere in the genome. In addition, the
10-bp site in the supF target gene used in these studies
would be expected to occur over 2000 other times in the
mouse cell genome. To target a unique sequence in the
mammalian genome, longer pcPNAs designed to bind to
target sites of 17bp or longer would be needed.
In addition, we did not detect any visible toxicity to the
cells upon pcPNA transfection beyond that seen from
simple electroporation alone. This is in keeping with the
favorable toxicity proﬁle of PNAs, even in whole animals
(34). Prior work with psoralen-linked TFOs demonstrated
that the cytotoxicity of psoralen plus UVA irradiation is
reduced by several orders of magnitude when the psoralen
is conjugated to a TFO (31). Our observations of cells
treated with psoralen-linked PNAs are consistent with
these previous studies of psoralen-TFOs.
The results furthermore indicate that a matched pair of
pcPNAs is required for eﬀective gene targeting; the
individual single-stranded PNAs, by themselves, were
ineﬀective. These results are in keeping with the in vitro
binding properties of the respective molecules on duplex
DNA. Interestingly, Janowski et al. (33) reported suppres-
sion of hPR gene expression in T47D human breast cancer
cells by transfection of individual single-stranded PNAs
designed to bind to one strand of the hPR gene in the
region of the transcription start site, presumably made
accessible due to the open complex produced by RNA
polymerase at the initiation of transcription. By compar-
ison, the ineﬀectiveness of the individual single-stranded
PNAs in our experiments may reﬂect the nature of the
target site in the supF gene, which is not transcribed in the
mouse cells and would not be expected to oﬀer special
accessibility.
The most important aspect of the results reported
here is the demonstration of targeted mutagenesis at a
mixed sequence chromosomal site as opposed to a
homopurine/homopyrimidine site as would be required
for triple helix formation. A number of previous studies
have documented the ability of TFOs to mediate site-
directed mutagenesis as well as to induce recombination in
a site-speciﬁc manner at chromosomal sites in mammalian
cells (5,6). However, TFOs can bind with high aﬃnity only
to sequences with purines on one strand and pyrimidines
on the other. While such sequences occur roughly once per
1000bp, and so most genes will contain at least one
polypurine site, the ability to target duplex DNA with
minimal sequence restriction has been a long-sought goal.
In principle, almost any site could be targeted with
pcPNAs. However, when only A and T are substituted,
prevention of PNA/PNA duplex formation requires at
least 40% A:T bp content, as in the pcPNA pair used here
(2640 and 2641). However, based on in vitro studies, an
A:T content of 50% or more would be preferable. Base
pairs 139–148 were chosen for targeting in the supF
gene even though this site only oﬀers the minimum of 40%
A:T content because it is adjacent to 50-TpA-30 and
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tides that are preferred sites for psoralen intercalation and
adduct formation. Hence, it remains to be determined
whether the eﬃciency of targeted mutagenesis by
pcPNAs would be higher if a site with  50% A:T bp
were targeted.
In addition, studies with PNAs and TFOs have
demonstrated that increased eﬃciencies of targeting
are obtained at highly transcribed loci compared to non-
transcribed loci (35,36). The supF gene is not transcribed
in the LN12 cells, and this may have limited the extent of
possible targeting by the pcPNAs. Other work has shown
that TFO-mediated targeting is elevated in synchronized
S-phase as opposed to G1-phase cells (37). The experi-
ments presented here were performed in unsynchronized
cell populations, and so it is possible that higher targeting
frequencies might be achieved in enriched S-phase cell
populations. As a result, the frequencies of targeted
mutagenesis in chromosomal loci by pcPNAs reported
here (in the range of 0.04%) represent a starting point for
this technology. Higher frequencies might also be expected
at diﬀerent loci with higher A:T content or greater
transcriptional activity. In theory, gene targeting by
pcPNAs could eventually have therapeutic applications.
However, additional strategies to increase the induced
mutation frequencies, such as improved delivery, may be
needed. Nonetheless, the work reported here demonstrates
that pcPNAs can mediate targeted mutagenesis in
mammalian cells at mixed sequence chromosomal sites,
thereby adding pcPNAs to the repertoire of gene targeting
agents and also expanding the proportion of the genome
that is amenable to targeting.
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